Cargando…

The Non-Peptide Arginine-Vasopressin v(1a) Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish

3,4-Methylenedioxymethamphetamine (MDMA) and its derivatives, 2,5-dimethoxy-4-bromo-amphetamine hydrobromide (DOB) and para-methoxyamphetamine (PMA), are recreational drugs whose pharmacological effects have recently been attributed to serotonin 5HT(2A/C) receptors. However, there is growing evidenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponzoni, Luisa, Braida, Daniela, Bondiolotti, Gianpietro, Sala, Mariaelvina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557732/
https://www.ncbi.nlm.nih.gov/pubmed/28855876
http://dx.doi.org/10.3389/fpsyt.2017.00146
_version_ 1783257253826002944
author Ponzoni, Luisa
Braida, Daniela
Bondiolotti, Gianpietro
Sala, Mariaelvina
author_facet Ponzoni, Luisa
Braida, Daniela
Bondiolotti, Gianpietro
Sala, Mariaelvina
author_sort Ponzoni, Luisa
collection PubMed
description 3,4-Methylenedioxymethamphetamine (MDMA) and its derivatives, 2,5-dimethoxy-4-bromo-amphetamine hydrobromide (DOB) and para-methoxyamphetamine (PMA), are recreational drugs whose pharmacological effects have recently been attributed to serotonin 5HT(2A/C) receptors. However, there is growing evidence that the oxytocin (OT)/vasopressin system can modulate some the effects of MDMA. In this study, MDMA (2.5–10 mg/kg), DOB (0.5 mg/kg), or PMA (0.005, 0.1, or 0.25 mg/kg) were administered intramuscularly to adult zebra fish, alone or in combination with the V(1a) vasopressin antagonist, SR49059 (0.01–1 ng/kg), before carrying out conditioned place preference (CPP), social preference, novel tank diving, and light–dark tests in order to evaluate subsequent rewarding, social, and emotional-like behavior. The combination of SR49059 and each drug progressively blocked: (1) rewarding behavior as measured by CPP in terms of time spent in drug-paired compartment; (2) prosocial effects measured on the basis of the time spent in the proximity of a nacre fish picture; and (3) anxiolytic effects in terms of the time spent in the upper half of the novel tank and in the white compartment of the tank used for the light–dark test. Antagonism was obtained at SR49059 doses which, when given alone, did not change motor function. In comparison with a control group, receiving vehicle alone, there was a three to five times increase in the brain release of isotocin (the analog of OT in fish) after treatment with the most active doses of MDMA (10 mg/kg), DOB (0.5 mg/kg), and PMA (0.1 mg/kg) as evaluated by means of bioanalytical reversed-phase high-performance liquid chromatography. Taken together, these findings show that the OT/vasopressin system is involved in the rewarding, prosocial, and anxiolytic effects of MDMA, DOB, and PMA in zebra fish and underline the association between this system and the behavioral alterations associated with disorders related to substance abuse.
format Online
Article
Text
id pubmed-5557732
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55577322017-08-30 The Non-Peptide Arginine-Vasopressin v(1a) Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish Ponzoni, Luisa Braida, Daniela Bondiolotti, Gianpietro Sala, Mariaelvina Front Psychiatry Psychiatry 3,4-Methylenedioxymethamphetamine (MDMA) and its derivatives, 2,5-dimethoxy-4-bromo-amphetamine hydrobromide (DOB) and para-methoxyamphetamine (PMA), are recreational drugs whose pharmacological effects have recently been attributed to serotonin 5HT(2A/C) receptors. However, there is growing evidence that the oxytocin (OT)/vasopressin system can modulate some the effects of MDMA. In this study, MDMA (2.5–10 mg/kg), DOB (0.5 mg/kg), or PMA (0.005, 0.1, or 0.25 mg/kg) were administered intramuscularly to adult zebra fish, alone or in combination with the V(1a) vasopressin antagonist, SR49059 (0.01–1 ng/kg), before carrying out conditioned place preference (CPP), social preference, novel tank diving, and light–dark tests in order to evaluate subsequent rewarding, social, and emotional-like behavior. The combination of SR49059 and each drug progressively blocked: (1) rewarding behavior as measured by CPP in terms of time spent in drug-paired compartment; (2) prosocial effects measured on the basis of the time spent in the proximity of a nacre fish picture; and (3) anxiolytic effects in terms of the time spent in the upper half of the novel tank and in the white compartment of the tank used for the light–dark test. Antagonism was obtained at SR49059 doses which, when given alone, did not change motor function. In comparison with a control group, receiving vehicle alone, there was a three to five times increase in the brain release of isotocin (the analog of OT in fish) after treatment with the most active doses of MDMA (10 mg/kg), DOB (0.5 mg/kg), and PMA (0.1 mg/kg) as evaluated by means of bioanalytical reversed-phase high-performance liquid chromatography. Taken together, these findings show that the OT/vasopressin system is involved in the rewarding, prosocial, and anxiolytic effects of MDMA, DOB, and PMA in zebra fish and underline the association between this system and the behavioral alterations associated with disorders related to substance abuse. Frontiers Media S.A. 2017-08-14 /pmc/articles/PMC5557732/ /pubmed/28855876 http://dx.doi.org/10.3389/fpsyt.2017.00146 Text en Copyright © 2017 Ponzoni, Braida, Bondiolotti and Sala. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Ponzoni, Luisa
Braida, Daniela
Bondiolotti, Gianpietro
Sala, Mariaelvina
The Non-Peptide Arginine-Vasopressin v(1a) Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish
title The Non-Peptide Arginine-Vasopressin v(1a) Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish
title_full The Non-Peptide Arginine-Vasopressin v(1a) Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish
title_fullStr The Non-Peptide Arginine-Vasopressin v(1a) Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish
title_full_unstemmed The Non-Peptide Arginine-Vasopressin v(1a) Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish
title_short The Non-Peptide Arginine-Vasopressin v(1a) Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish
title_sort non-peptide arginine-vasopressin v(1a) selective receptor antagonist, sr49059, blocks the rewarding, prosocial, and anxiolytic effects of 3,4-methylenedioxymethamphetamine and its derivatives in zebra fish
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557732/
https://www.ncbi.nlm.nih.gov/pubmed/28855876
http://dx.doi.org/10.3389/fpsyt.2017.00146
work_keys_str_mv AT ponzoniluisa thenonpeptideargininevasopressinv1aselectivereceptorantagonistsr49059blockstherewardingprosocialandanxiolyticeffectsof34methylenedioxymethamphetamineanditsderivativesinzebrafish
AT braidadaniela thenonpeptideargininevasopressinv1aselectivereceptorantagonistsr49059blockstherewardingprosocialandanxiolyticeffectsof34methylenedioxymethamphetamineanditsderivativesinzebrafish
AT bondiolottigianpietro thenonpeptideargininevasopressinv1aselectivereceptorantagonistsr49059blockstherewardingprosocialandanxiolyticeffectsof34methylenedioxymethamphetamineanditsderivativesinzebrafish
AT salamariaelvina thenonpeptideargininevasopressinv1aselectivereceptorantagonistsr49059blockstherewardingprosocialandanxiolyticeffectsof34methylenedioxymethamphetamineanditsderivativesinzebrafish
AT ponzoniluisa nonpeptideargininevasopressinv1aselectivereceptorantagonistsr49059blockstherewardingprosocialandanxiolyticeffectsof34methylenedioxymethamphetamineanditsderivativesinzebrafish
AT braidadaniela nonpeptideargininevasopressinv1aselectivereceptorantagonistsr49059blockstherewardingprosocialandanxiolyticeffectsof34methylenedioxymethamphetamineanditsderivativesinzebrafish
AT bondiolottigianpietro nonpeptideargininevasopressinv1aselectivereceptorantagonistsr49059blockstherewardingprosocialandanxiolyticeffectsof34methylenedioxymethamphetamineanditsderivativesinzebrafish
AT salamariaelvina nonpeptideargininevasopressinv1aselectivereceptorantagonistsr49059blockstherewardingprosocialandanxiolyticeffectsof34methylenedioxymethamphetamineanditsderivativesinzebrafish